MITOGEN ADVANCED DIAGNOSTICS

2016-17 Schedule of Autoantibody Tests & Turnaround Times

 

Name of Test/Assay Procedure/Technique Turnaround time (Days)*
Anti-Cellular Antibody IIF on HEp-2 substrate with pattern interpretation 5
Antiphospholipid syndrome:

·       anti-PS/PT: IgG, IgM (replaces lupus inhibitor)

·       b2GP1 Domain 1

 

ELISA

CIA

 

5

5

Arthritis Profile:

Anti-Citrullinated Peptide Profile: HCP1, HCP2, VCP1, VCP2; RF

 

ALBIA/ELISA

 

5

Cancer Associated Autoantibody Panel:  p53, CENP-F  

ALBIA (RUO)

 

14

Cell Cycle Pattern Profile ALBIA (RUO) 7
Cytoplasmic dot panel
(GW Bodies/GW182, Ago2, Ge-1; endosome/ EEA1)
 

ALBIA (RUO)

 

7

Dense Fine Speckles pattern: DFS70/LEDGF CIA 7
Dermatology: Bullous Autoimmune Dermatoses Profile CBA 7
DNA Antibodies

·       ssDNA

·       dsDNA (quanititative for SLE disease activity)

 

ELISA

CIA

 

7

5

Drug-Induced Lupus: anti-histone LIA 7
Gastrointestinal:

Inflammatory Bowel Disease ASCA (IgG, IgA)

 

ELISA

 

5

Liver:

·       Autoimmune Liver Disease panel (AIH/PBC): M2, M3/3E-BPO, gp210, SP100, SLA, PML, LC-1, Ro52

 

LIA

 

7

Lung:

·       ILD Profile

·       Alveolar Proteinosis (GMCSF)

 

LIA, IIF

ALBIA (RUO)

 

7

7

Muscle:

Inclusion Body Myositis:

Anti-Mup44/NT5C1A

 

 

ALBIA (RUO)

 

 

10

Muscle: Autoimmune Myositis Panel for Dermatomyositis, Polymyositis, Synthetase Syndrome: Jo-1, PL-7, PL-12, OJ, EJ, KS, Zo, PM/Scl, SRP,  MDA-5, SAE, NXP-2, TIF1g  

LIA

 

7

Muscle:

Immune Mediated Necrotizing Myopathy

Statin Related Myopathy :

anti-HMGCR, anti-SRP

 

 

 

ELISA ,LIA

 

 

 

7

Nephritis:

  • Idiopathic membranous nephropathy

Anti-PLA2R

  • Primary Membranous Nephropathy

Anti-THSD7A

 

 

CBA

 

CBA

 

 

10

 

10

Neurological: Autoimmune

IgG and IgM gangliosides

 

LIA

 

7

Neurological:

Demyelinating disease(NMO)

(anti-MOG)

 

 

CBA/ELISA

 

 

7

 

Neurological: encephalitis

·       anti- NMDA receptor: NR1

·       anti-DPPX

·       anti-GABAB Receptor

 

CBA

CBA

CBA

 

7

7

7

Neurological: Voltage Gated Potassium Channel

(VGKC – LGI1, Caspr2)

 

CBA

 

7

Neurological: Neuromyelitis optica spectrum. Anti-aquaporin  

CBA

 

7

Neurological: MAG (myelin associated glycoprotein)  

MAG

 

10

Neurological:

Idiopathic Ataxia, MPP-1

 

ALBIA (RUO)

 

10

Neurological/Cancer:
Paraneoplastic  panel
LIA 7
Neurological: AMPA Receptor CBA 7
Neurological: GAD65 CBA 7
Nuclear Envelope/Membrane  Profile(RUO): laminB, gp210, Tpr  

ALBIA(RUO)

 

7

Nucleolar Autoantibody Profile: PM/Scl, Th/To, fibrillarin, NOR-90, RNAP III  

IIF/ LIA

 

7

Scleroderma/Systemic Sclerosis Profile: CENP, Scl-70/topo I, RNA polymerase III, PM/Scl, fibrillarin, Th/To, Ro52, NOR-90

 

LIA 7
Sjögren’s Syndrome Profile:

SS-B/La, SS-A/Ro60, Ro52

 

ALBIA/LIA

 

7

Systemic Lupus profile:

Sm, U1RNP, ribosomal P, dsDNA, SS-A/Ro60, SSB/La, Ro52, Ku, C1q, Chromatin, PCNA

 

LIA/ELISA

 

5

Systemic Lupus Disease Activity: quantitative dsDNA  

CIA dsDNA

 

7

Vasculitis Panel:

  • ANCA( PR3,MPO)
  • Atypical ANCA (LAMP2, Elastase)
 

CIA/ABLIA

 

 

7

 

 

*** Target date July 1, 2016

 

Abbreviations:

AIH: autoimmune hepatitis; ALBIA: addressable laser bead immunoassay by Luminex; AMPAR: (a-amino-3-hydroxy-5-mehtyl-4-isoxasole proprionate receptor): limbic encephalitis ANA: antinuclear antibody; ASCA: anti-Saccharomyces cerevisiae antibody; CarP: carbamylated protein; CBA: cell based assay; CENP: centromere protein; CIA: chemiluminescence assay (BioFlash); DPPX: dipeptidyl peptidase like 6; EEA-1: early endosome antigen 1; ELISA: enzyme linked immunosorbent assay; GAD: glutamate decarboxylase; GM-CSF: granulocyte macrophage colony stimulating factor; IBD: inflammatory bowel disease; IIF: indirect immunofluorescence; LIA: line immunoassay; MAG: myelin associate glycoprotein; MecP2: methyl CpG binding protein 2; MPO: myeloperoxidase; MPP: M-phase phosphoprotein 1; NMDA: N-methyl-D-aspartic acid; NMO: neuromyelitis optica spectrum (Devic’s Diseases); PBC: primary biliary cirrhosis; PR3: proteinase 3; PS/PT: phosphatidyl serine/prothrombin complex; SARD: systemic autoimmune rheumatic diseases (SLE, scleroderma, myositis, Sjögren’s syndrome); VGKC: voltage gated potassium channel,

 

Disease and Autoantibody Related Autoantibody Panels

  • Anti-phospholipid syndrome: anti-prothrombin/phosphatidyl serine complex (PS/PT): replaces lupus anti-coagulant/lupus inhibitor; b2GP1 Domain 1: more specific epitope for APS than intact b2GP1.
  • Arthritis Panel: Anti-Citrullinated peptide profile: 4 new citrullinated peptides including mutated vimentin/Sa,   Carbamylated protein (CarP), RF: rheumatoid factor.
  • Interstitial Lung Disease Profile: anti-MDA5, Jo1, PL-7, PL-12, Ro52/TRIM21, Th/To, Topo I.
  • Cell Cycle Profile: PCNA, CENP-F, NuMa, HSeg5, pericentrin (centrosome)
  • Nucleolar Antibody Panel: anti-PM/Scl75, Th/To, fibrillarin, RNA polymerase III
  • Nuclear envelope autoantibody Panel: anti-lamin B, gp210, Tpr
  • Scleroderma Profile: Th/To, topoisomerase I (Scl-70), PM/Scl, fibrillarin, PDGFR, PM/Scl 75, PM/Scl 100, RNA polymerase III, Ku.
  • Systemic Lupus Profile: anti-Sm, U1RNP, Ribosomal P, SSA/Ro60, anti-dsDNA, PCNA, anti-chromatin, anti-C1q, Ku.
  • Systemic Lupus Erythematosus Disease Activity: dsDNA: for patients who were previously tested by Mitogen and clinician following anti-dsDNA titers as a parameter of disease activity.
  • Sjögren’s Syndrome Profile: anti-Ro52/TRIM21, SSB/La, SSA/Ro60, NuMa, MSA1, HsEg5, Golgi complex, GW bodies (GW182, Ago-2, Ge-1).